martes, 17 de marzo de 2015
Si es BAYER es...ambicioso: 25 billion euros en 2017
(Bloomberg) -- Bayer AG intends to increase health-care sales by an average of about 6 percent a year through 2017 to more than 25 billion euros ($27 billion) as the company focuses on life sciences and exits the plastics industry.
The unit also is targeting an operating margin before special items of 29 percent to 31 percent, compared with 27.5 percent last year, the Leverkusen, Germany-based company said in a statement today.
“The outlook for our health-care business is particularly positive thanks to the five pharmaceutical products we recently launched,” Chief Executive Officer Marijn Dekkers said in the statement. The products include anticoagulant Xarelto, eye medicine Eylea and two cancer drugs.
Bayer is focusing its drug development on heart disease, hematology, cancer and gynecology, and will benefit from its purchase of Merck & Co.’s over-the-counter medicines business for $14.2 billion last year.